172@29@17@143!~!172@29@0@53!~!|news|tags|aurobindo-pharma.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
aurobindo pharma
Jump to
2034 Results Found
  • Buy Aurobindo Pharma; target of Rs 985: Motilal Oswal Oct 28, 2020 01:19 PM IST

    Buy Aurobindo Pharma; target of Rs 985: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 985 in its research report dated October 26, 2020.

  • Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct Oct 27, 2020 02:00 PM IST

    Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct

    ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated October 26, 2020.

  • Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy Oct 27, 2020 09:24 AM IST

    Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy

    The Natrol sale will help Aurobindo Pharma focus on the core generic drug and injectable businesses

  • Aurobindo Pharma share price rises 4% as subsidiary sells business assets Oct 26, 2020 10:34 AM IST

    Aurobindo Pharma share price rises 4% as subsidiary sells business assets

    Jefferies served as the sole financial adviser and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo.

  • Buy Aurobindo Pharma; target of Rs 1030: Motilal Oswal Sep 28, 2020 11:22 PM IST

    Buy Aurobindo Pharma; target of Rs 1030: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1030 in its research report dated September 27, 2020.

  • Buy Aurobindo Pharma; target of Rs 975: Sharekhan Sep 23, 2020 12:14 PM IST

    Buy Aurobindo Pharma; target of Rs 975: Sharekhan

    Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 975 in its research report dated September 22, 2020.

  • Aurobindo Pharma: Shot in the arm for Covid vaccine development programme Sep 16, 2020 09:40 AM IST

    Aurobindo Pharma: Shot in the arm for Covid vaccine development programme

    Vaccine capacity creation puts Aurobindo in the league of Serum Institute of India and Cadila in the race for a Covid drug

  • Aurobindo Pharma ties up with BIRAC to develop COVID-19 vaccine Sep 15, 2020 06:35 PM IST

    Aurobindo Pharma ties up with BIRAC to develop COVID-19 vaccine

    Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines.

  • Buy Aurobindo Pharma; target of Rs 1027: KR Choksey Aug 19, 2020 11:07 AM IST

    Buy Aurobindo Pharma; target of Rs 1027: KR Choksey

    KR Choksey is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1027 in its research report dated August 17, 2020.

  • Buy Aurobindo Pharma; target of Rs 1000: Emkay Global Financial Aug 17, 2020 05:06 PM IST

    Buy Aurobindo Pharma; target of Rs 1000: Emkay Global Financial

    Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1000 in its research report dated August 13, 2020.

  • Hold Aurobindo Pharma; target of Rs 838: Prabhudas Lilladher Aug 16, 2020 09:08 AM IST

    Hold Aurobindo Pharma; target of Rs 838: Prabhudas Lilladher

    Prabhudas Lilladher recommended Hold rating on Aurobindo Pharma with a target price of Rs 838 in its research report dated August 13, 2020.

  • Hold Aurobindo Pharma; target of Rs 975: Sharekhan Aug 16, 2020 07:21 AM IST

    Hold Aurobindo Pharma; target of Rs 975: Sharekhan

    Sharekhan recommended Hold rating on Aurobindo Pharma with a target price of Rs 975 in its research report dated August 13, 2020.

  • Buy Aurobindo Pharma; target of Rs 1055: Motilal Oswal Aug 16, 2020 07:20 AM IST

    Buy Aurobindo Pharma; target of Rs 1055: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1055 in its research report dated August 13, 2020.

  • Aurobindo Pharma: Debt reduction lends confidence Aug 14, 2020 12:22 PM IST

    Aurobindo Pharma: Debt reduction lends confidence

    Aurobindo is building capacities for emerging drug delivery systems in the US and could be a key beneficiary of the localisation initiative there

  • Buy Aurobindo Pharma; target of Rs 1100: ICICI Direct Aug 14, 2020 12:22 PM IST

    Buy Aurobindo Pharma; target of Rs 1100: ICICI Direct

    ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated August 13, 2020.

  • Aurobindo Pharma shares fall 3% despite a 22% jump in Q1 profit Aug 13, 2020 09:51 AM IST

    Aurobindo Pharma shares fall 3% despite a 22% jump in Q1 profit

    At operating level, its earnings before interest, tax, depreciation and amortisation (EBITDA) rose 9.7 percent YoY to Rs 1,257.4 crore, and margin expanded 10 bps to 21.2 percent in Q1FY21, compared to same period last year.

  • Aurobindo Pharma Q1 profit jumps 23% to Rs 781 crore Aug 12, 2020 09:19 PM IST

    Aurobindo Pharma Q1 profit jumps 23% to Rs 781 crore

    Revenue from operations for the quarter under review at Rs 5,924.8 crore increased by 8.8 percent YoY, with US formulation business showing a 15.6 percent growth at Rs 3,107.1 crore

  • Trade Spotlight: Aarti Drugs, Caplin Point & Aurobindo Pharma hit 52-week high, what should investors do? Aug 07, 2020 08:22 AM IST

    Trade Spotlight: Aarti Drugs, Caplin Point & Aurobindo Pharma hit 52-week high, what should investors do?

    Experts are of the view that investors should trade with caution, and a more sustainable move can be seen only a close above 11225. Immediate support is placed at 11,100 levels.

  • Aurobindo Pharma share price at 52-week high on US FDA nod to blood pressure drug Jul 09, 2020 10:10 AM IST

    Aurobindo Pharma share price at 52-week high on US FDA nod to blood pressure drug

    The stock, which has surged 86 percent in the last three months, hitting a new high of Rs 821.90.

  • After a strong Q4 FY20, these 5 companies can return 10-30% Jul 08, 2020 11:00 AM IST

    After a strong Q4 FY20, these 5 companies can return 10-30%

    The brokerage now expects Nifty earnings to grow at a CAGR of 16 percent over FY20-22, albeit on a low base and values the Nifty at 10,300 i.e. 1.2x PEG on FY22E EPS of Rs 543 with corresponding Sensex target placed at 34,800.

  • F&O expiry: These 4 stocks have given at least 10% return in last 3 series Jun 25, 2020 03:05 PM IST

    F&O expiry: These 4 stocks have given at least 10% return in last 3 series

    The four stocks that were winners in last 3 series were M&M, Vodafone Idea, Balkrishna Industries and Aurobindo Pharma

  • Developing a range of products for US, EU markets: Aurobindo Pharma Jun 25, 2020 03:00 PM IST

    Developing a range of products for US, EU markets: Aurobindo Pharma

    The firm is developing eight inhalers and six nasal sprays, out of which two products have already been filed, Aurobindo Pharma Managing Director N Govindarajan said in an analyst call.

  • Pricing problems: Aurobindo Pharma, Sun Pharma, Lupin named in lawsuit in US Jun 12, 2020 08:20 AM IST

    Pricing problems: Aurobindo Pharma, Sun Pharma, Lupin named in lawsuit in US

    Attorney General Brian E Frosh in a statement issued on Wednesday said the new complaint, filed in the U.S. District Court for the District of Connecticut, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and the complaint names 26 corporate defendants and 10 individual defendants.

  • Buy Aurobindo Pharma; target of Rs 835: Emkay Global Financial Jun 07, 2020 08:50 PM IST

    Buy Aurobindo Pharma; target of Rs 835: Emkay Global Financial

    Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 835 in its research report dated June 04, 2020.

  • Buy Aurobindo Pharma; target of Rs 880: Motilal Oswal Jun 07, 2020 08:36 PM IST

    Buy Aurobindo Pharma; target of Rs 880: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 880 in its research report dated June 04, 2020.

Sections